Last reviewed · How we verify
Stapokibart injection — Competitive Intelligence Brief
phase 3
Biologic
Live · refreshed every 30 min
Target snapshot
Stapokibart injection (Stapokibart injection) — Chengdu Kangnuoxing Biopharma,Inc.. Stapokibart injection is designed to target and modulate a specific pathway involved in the disease process, though the exact mechanism is not publicly detailed.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Stapokibart injection TARGET | Stapokibart injection | Chengdu Kangnuoxing Biopharma,Inc. | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Stapokibart injection CI watch — RSS
- Stapokibart injection CI watch — Atom
- Stapokibart injection CI watch — JSON
- Stapokibart injection alone — RSS
Cite this brief
Drug Landscape (2026). Stapokibart injection — Competitive Intelligence Brief. https://druglandscape.com/ci/stapokibart-injection. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing